Extracellular vesicle (EV)-associated non-coding RNAs (ncRNAs) are increasingly recognized as mediators of intercellular communication within the tumor microenvironment (TME), yet their mechanistic and translational significance varies substantially across gastrointestinal and hepatobiliary cancers. This narrative review, informed by a structured literature search, integrates evidence on EV-associated microRNAs, long non-coding RNAs, and circular RNAs in esophageal, gastric, colorectal, pancreatic, hepatocellular carcinoma, and cholangiocarcinoma. Rather than organizing the literature by RNA class or individual tumor type, we synthesize findings according to major TME functions, including immune remodeling, cancer-associated fibroblast activation, vascular remodeling, paracrine tumor-cell reprogramming, therapy resistance, and tumor-suppressive vesicular signaling. Recurrent mechanisms involve PTEN/PI3K/AKT, JAK/STAT, TGF-β/Smad, Wnt/β-catenin, and immune-checkpoint pathways, but the strength of evidence differs markedly among studies. Accordingly, mechanistic findings are distinguished from animal-model-supported, clinically correlated, preliminary, and biomarker-only evidence using a standardized descriptive framework. The review also highlights cholangiocarcinoma as an underrepresented but increasingly informative hepatobiliary model while avoiding generalization to broader biliary tract cancers when direct evidence is lacking. Major barriers to clinical translation include inconsistent EV isolation and characterization, uncertain vesicle-source attribution, limited validation of recipient-cell transfer and causal targets, small retrospective cohorts, and insufficient prospective validation. Overall, EV-ncRNAs represent promising mechanistic biomarkers and therapeutic targets, but rigorous source-specific validation and standardized analytical workflows are required before clinical implementation.
T. Alramadneh, Waleed K. Abdulsahib, Sanan Thaer Abdal-Wahab et al.· Cancer Treatment and Researc...· 0 citations
Gastric cancer (GC) remains a leading cause of cancer-related mortality, with chemoresistance posing a critical barrier to effective treatment. Tumor-associated macrophages (TAMs), particularly the immunosuppressive M2-polarized subset, are emerging as pivotal mediators of chemoresistance within the tumor microenvironment (TME). TAMs promote resistance through multifaceted mechanisms, including activation of pro-survival signaling pathways, induction of epithelial-mesenchymal transition (EMT), and enhancement of angiogenesis. For instance, M2-like TAMs secrete CXCL5, which activates the PI3K/AKT/mTOR axis in GC cells, thereby conferring resistance to 5-fluorouracil (5-FU). Similarly, TMEM, a transmembrane protein overexpressed in cisplatin-resistant GC, drives M2 polarization of TAMs via the Wnt/β-catenin pathway, further amplifying drug resistance and tumor progression. Clinical studies reveal that high TAM infiltration correlates with poor chemotherapy response and reduced survival in GC patients. This review synthesizes current evidence on TAM-driven chemoresistance in GC, highlighting the molecular interplay between TAMs, tumor cells, and stromal components. It underscores the potential of TAM-centric therapies-including checkpoint inhibitors, epigenetic modulators, and combination regimens-to overcome resistance and improve clinical outcomes. By integrating preclinical insights and clinical data, this work provides a roadmap for developing precision therapies that exploit TAM biology to enhance chemosensitivity in GC.
S. Abdul-Rahman, Abdulkareem Shareef, S. Jyothi et al.· Cell Biology International· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.